Class summary at a glance.

Every drug in the Parathyroid Hormone Analog class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $757.1Mcombined across class
Total Rx claims: 240K53K unique beneficiaries
Generic mfrs (active): 3across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Teriparatide

Brand: Bonsity · 240K Part D claims (CY24) · 53K beneficiaries · First FDA approval: 2002-11-26

3 generic mfrs 472 plans require PA

Low NADAC$595.54

→

Avg plan cost$872.16

Part D spend $757.1M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.